ReviewChinese medicine2026
44-year journey (1980-2024): scientometric insights into Sigesbeckiae herba and update on its medicinal properties and phytochemicals profile.
Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study uses Scientometric analysis to review Sigesbeckiae Herba (SH) research worldwide from 1980 to 2024. Data-driven analysis identifies patterns, partnerships, and possibilities. Due to its wide profile and traditional medical uses, SH is gaining attention, according to this research. China has made the most important contributions to SH research, followed by the United stated of America and Korea. Countries and organizations have not collaborated on SH research. We found "anti-inflammation," "rheumatic arthritis," and "NF-κβ" using keyword co-occurrence analysis. Citation analysis showed SH research's most prominent institutions, journals, and authors, offering a complete snapshot of organization and diffusion. The data shows that this subject has received substantial academic interest despite a reduction in publications since 2019. These findings highlight the need for cooperation, multidisciplinary methods, and attention to underrepresented disciplines for academics, funding organizations, and policymakers. SH has been used to cure inflammation. Sigesbeckia orientalis L., S. pubescens Makino, and S. glabrescens Makino are the primary botanical sources. This research extensively evaluates SH literature, focusing on its botanical properties, bioactive components, pharmacological effects, and probable toxicity. More than three hundred phytochemicals, including flavonoids, diterpenoids, sesquiterpenoids, oxylipins, and lignoids, were identified in the extract, many of which are known to exert diverse biological effects. The extracts of SH are used in traditional Chinese medicine (TCM) due to its immunomodulatory, anti-inflammatory, and anti-cancer activities and are being considered for cosmetics and skin issues. Pharmacological benefits of diterpenoids, sesquiterpenoids, and flavonoids are found. The study recommends further research and cooperation to enhance TCM and herbal research by comparing the chemical and pharmacological properties of these three SH species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.